Introduction
Relugolix, sold under the trade name Orgovyx, is an oral gonadotropin-releasing hormone (GnRH) antagonist used to treat advanced prostate cancer. It offers a convenient alternative to injectable therapies, providing rapid testosterone suppression without the initial testosterone surge (flare) seen with LHRH agonists.
Purpose
- Treats advanced prostate cancer by lowering testosterone levels.
- Provides an oral option for androgen deprivation therapy (ADT).
- Rapidly reduces testosterone without causing a flare, offering a safer alternative for certain patients.
How It Works
Relugolix blocks GnRH receptors in the pituitary gland, leading to a rapid decrease in luteinizing hormone (LH) and testosterone production. This direct mechanism avoids the initial surge in testosterone associated with LHRH agonists.
Usage
- Taken as an oral tablet, typically once daily.
- No loading dose is required; testosterone suppression begins rapidly with the first dose.
- Periodic monitoring of PSA levels, testosterone levels, and overall health is recommended during treatment.
Considerations
- Common side effects include hot flashes, fatigue, and mild gastrointestinal discomfort.
- Rare but serious side effects include cardiovascular events and osteoporosis; patients should be monitored closely.
- Oral administration provides flexibility but requires adherence to daily dosing.
At Crossroads Urology
At Crossroads Urology, Relugolix is a convenient and effective option for patients needing testosterone suppression. Our providers work closely with patients to ensure safe and effective treatment while minimizing side effects.
Conclusion
Relugolix [Orgovyx] offers a modern, oral approach to testosterone suppression for advanced prostate cancer, providing convenience and efficacy without the risks of a testosterone surge. Contact Crossroads Urology today to learn more about this treatment and how it can improve your prostate cancer care.